Expert Highlights Caution for Chemo Substitutions for Gynecologic Cancers

Commentary
Video

Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.

Brian Slomovitz, MD, MS, FACOG, spoke with CancerNetwork® about the potential impact of substituting platinum-based chemotherapy for other platinum-based agents in the treatment of those with gynecologic cancers during the ongoing chemotherapy shortage in the United States.

Slomovitz, a gynecologic oncologist, director of Gynecologic Oncology, and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, Florida and a professor of Obstetrics and Gynecology at Florida International University, emphasized caution when making the decision to switch from carboplatin to cisplatin, or vice versa, as it is unclear how the change may impact patient outcomes or quality of life. He did note that the substitution does make sense in theory, but also stated it’s important to remember that they’re different agents.

Additionally, he spoke about how guidelines from organizations such as the Society of Gynecologic Oncology (SGO) may help in guiding treatment decision-making during the platinum-based chemotherapy shortages.

Transcript:

The quality of life definitely [is impacted] for a lot of perspectives, because the [adverse] effect profiles can be different and things like that. We've had to make some changes. We've written some consensus pieces on that, part of it with the Society of Gynecologic Oncology [SGO], which are nice guides of what to do in the setting. But there is some unknown. When we've studied thousands of patients for certain diseases like ovarian cancer with carboplatin, and then we say, ‘Hey, let's switch. Let's give cisplatin.’ Theoretically, it makes sense. But the bottom line is they're different drugs. I don't want to say to keep our fingers crossed; it's a little bit more scientific than that. But we're cautious that the efficacy is going to be the same.

Reference

SGO statement: carboplatin and cisplatin shortages. News release. Society of Gynecologic Oncology. April 21, 2023. Accessed August 7, 2023. https://tinyurl.com/y3dcmdk4

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
Related Content